New Mechanisms: Cardior’s Non-Coding RNA Therapeutic For Heart Failure
MicroRNAs Also Of Interest To Other Biotechs
Executive Summary
Germany’s Cardior is conducting clinical studies with an antisense oligonucleotide which inhibits a cellular microRNA believed to be involved in the pathology of heart failure, and is attracting attention from other pharma companies interested in the potential of this new mechanism of action.
You may also be interested in...
BIO-Europe Spring 2019: InteRNA Sees MicroRNA Potential In Cancer Therapy
Roel Schaapveld is CEO of Dutch microRNA specialist InteRNA Technologies. He spoke to Mike Ward about the company’s therapeutic approach.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.